Although MR studies have investigated the effects of LPL pathway activation on CAD and T2D liability, they have been limited to specific outcomes, and their modes of action, drug target interactions, and safety have not been comprehensively investigated. The gene discussed is LPL; the disease is type 2 diabetes mellitus.